Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Rocbrutinib vs Pirtobrutinib w R/R CLL/SLL wcześniej leczonym cBTKi (faza 3)

11 listopada 2026 zaktualizowane przez: Newave Pharmaceutical Inc

Faza 3 otwartego, randomizowanego, wieloośrodkowego badania rocbrutynibu (LP-168) w porównaniu z pirtobrutynibem u pacjentów z nawrotowym lub opornym przewlekłym białaczkiem limfocytową (CLL) / chłoniakiem z małych limfocytów (SLL) wcześniej leczonych kowalencyjnym inhibitorem BTK (cBTKi)

This is a Phase 3, randomized, open-label, multicenter study comparing rocbrutinib (LP-168) versus pirtobrutinib in adult participants with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received a covalent Bruton's tyrosine kinase inhibitor (cBTKi). Approximately 306 participants will be randomized 1:1 to receive rocbrutinib 200 mg orally once daily or pirtobrutinib 200 mg orally once daily, administered continuously in 28-day cycles until disease progression, unacceptable toxicity, withdrawal of consent, or other discontinuation criteria are met. Randomization will be stratified by presence of del(17p)/TP53 mutation (yes/no), reason for discontinuation of prior cBTKi therapy (toxicity vs disease progression), prior exposure to a BCL2 inhibitor (yes/no), and region (United States/China/rest of world). The primary endpoint is progression-free survival (PFS) assessed by an independent review committee (IRC) using iwCLL 2018 criteria for CLL and Lugano 2014 criteria for SLL. Key secondary objectives include overall survival, overall response rate, time-to-event outcomes, and safety/tolerability; exploratory objectives include health-related quality of life and biomarker assessments.

Przegląd badań

Szczegółowy opis

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are indolent B-cell malignancies characterized by accumulation of mature but dysfunctional lymphocytes. Covalent Bruton's tyrosine kinase inhibitors (cBTKis) have substantially improved outcomes for patients with CLL/SLL; however, disease progression on cBTKi therapy or intolerance leading to treatment discontinuation remains an important clinical challenge. Patients who discontinue cBTKi therapy due to progression have limited therapeutic options and may experience poor outcomes. Therefore, effective and well-tolerated therapies are needed for participants with relapsed or refractory (R/R) CLL/SLL who have previously received a covalent BTK inhibitor.

Rocbrutinib (LP-168) is a selective next-generation inhibitor of BTK, that can irreversibly inhibit WT BTK, and reversibly inhibit C481 mutated BTK, with activity against known resistance mutations for non-covalent BTKi, under investigation for the treatment of CLL/SLL. Pirtobrutinib is an oral BTK inhibitor with regulatory approval for adults with R/R CLL/SLL who have previously received a covalent BTK inhibitor (cBTKi). This Phase 3 study is designed to compare the efficacy and safety of rocbrutinib versus pirtobrutinib in adult participants with cBTKi-pretreated R/R CLL/SLL.

This is a Phase 3, randomized, open-label, multicenter study conducted at approximately 100 sites globally. Approximately 306 participants will be randomized in a 1:1 ratio to receive rocbrutinib (LP-168) or pirtobrutinib. Eligible participants are adults with confirmed R/R CLL or SLL who require therapy and have received prior treatment with a cBTKi. Participants may have received additional prior systemic therapies, including prior exposure to a BCL2 inhibitor. Key exclusion criteria include central nervous system involvement by CLL/SLL and clinically significant cardiovascular conditions, including uncontrolled arrhythmias and clinically relevant QTc prolongation.

Participants randomized to the investigational arm will receive rocbrutinib 200 mg orally once daily. Participants randomized to the active comparator arm will receive pirtobrutinib 200 mg orally once daily. Study treatments will be administered continuously in 28-day cycles until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-defined discontinuation criteria. Crossover between treatment arms is not permitted.

Randomization will be stratified based on prognostic and treatment-history factors, including: (1) del(17p) and/or TP53 mutation status, (2) reason for discontinuation of prior cBTKi therapy, (3) prior exposure to a BCL2 inhibitor, and (4) geographic region.

The primary endpoint is progression-free survival (PFS). PFS will be assessed by an independent review committee (IRC) to provide objective evaluation of disease status. Response and progression for participants with CLL will be assessed according to iwCLL 2018 criteria, while participants with SLL will be assessed using Lugano 2014 criteria.

Key secondary efficacy endpoints include overall survival (OS), overall response rate (ORR), duration of response (DOR), time to next treatment (TTNT), and event-free survival (EFS). Additional secondary objectives include characterization of the safety and tolerability of rocbrutinib relative to pirtobrutinib. Safety will be assessed through evaluation of adverse events (AEs), serious adverse events (SAEs), adverse events of special interest, deaths, physical examinations, vital signs, electrocardiograms, and clinical laboratory assessments. AEs will be graded using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. In addition, population pharmacokinetics will be evaluated to characterize exposure-response relationships.

Exploratory objectives include evaluation of patient-reported outcomes and health-related quality of life, as well as biomarker assessments aimed at characterizing disease biology, mechanisms of response and resistance, and potential predictors of clinical benefit.

Typ studiów

Interwencyjne

Zapisy (Szacowany)

306

Faza

  • Faza 3

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Kopia zapasowa kontaktu do badania

Lokalizacje studiów

      • Le Mans, Francja, 72037
        • Rekrutacyjny
        • Centre Hospitalier Le Mans
    • Illinois
      • Skokie, Illinois, Stany Zjednoczone, 60077
        • Rekrutacyjny
        • Orchard Healthcare Research
    • Maryland
      • Bethesda, Maryland, Stany Zjednoczone, 20817
        • Rekrutacyjny
        • The Center for Cancer and Blood Disorders-Bethesda
    • Nevada
      • Las Vegas, Nevada, Stany Zjednoczone, 89102
        • Rekrutacyjny
        • Optum Medical Group (Rhodes) P.C.
    • North Carolina
      • Durham, North Carolina, Stany Zjednoczone, 27705
        • Rekrutacyjny
        • Duke Adult Blood and Marrow Clinic
    • Ohio
      • Columbus, Ohio, Stany Zjednoczone, 43210
        • Jeszcze nie rekrutacja
        • OSU Comprehensive Cancer Center
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Stany Zjednoczone, 15213
        • Rekrutacyjny
        • UPMC Hillman Cancer Center
    • Washington
      • Spokane, Washington, Stany Zjednoczone, 99208
        • Rekrutacyjny
        • Medical Oncology Associates - Spokane

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • Age ≥18 years;
  • Histologically confirmed CLL/SLL iwCLL 2018;
  • Relapsed or refractory disease requiring treatment;
  • Previously treated with prior lines of therapy including a covalent BTK inhibitor;
  • Measurable disease;
  • ECOG 0-2;
  • Adequate marrow, hepatic, and renal function;
  • TP53 mutation status confirmed by NGS;
  • 17p deletion status confirmed by FISH;

Exclusion Criteria:

  • Prior ncBTKi or BTK degraders;
  • Richter's transformation;
  • Confirmed prolymphocytic leukemia;
  • Uncontrolled comorbidities or infections;
  • Known CNS involvement by CLL/SLL;
  • Prior malignancy requiring active treatment (except certain adequately treated cancers) per protocol;
  • Pregnancy or breastfeeding;
  • Concomitant medications or conditions prohibited by protocol (e.g., strong drug-drug interaction risk);

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Rocbrutinib

200mg daily

The new generation, highly potent, ultra-selective BTK inhibitor with covalent and non-covalent dual binding mechanism, targeting both WT BTK and mutant BTK

Aktywny komparator: Pirtobrutinib

200mg daily

Pirtobrutinib is a non-covalent BTK inhibitor.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
PFS assessed by IRC
Ramy czasowe: From randomization until disease progression or death from any cause, assessed up to approximately 4 years.

Progression-Free Survival assessed by independent review committee. PFS is defined as the time from the date of randomization to disease progression or death from any cause, whichever occurs first. Those who do not experience disease progression or death at the time of analysis are censored according to the last evaluation time point.

From randomization until disease progression or death from any cause, assessed up to approximately 4 years.

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
OS
Ramy czasowe: From randomization until death from any cause, assessed up to approximately 4 years

Overall survival is defined as the time from the date of randomization to death from any cause. Those who did not die during the analysis were censored according to the last date the subject is known to be alive.

From randomization until death from any cause, assessed up to approximately 4 years
PFS assessed by INV
Ramy czasowe: From randomization until disease progression or death from any cause, assessed up to approximately 4 years.

Progression free survival assessed by investigator

From randomization until disease progression or death from any cause, assessed up to approximately 4 years.
ORR
Ramy czasowe: From randomization until disease progression, assessed up to approximately 4 years

Overall response rate

From randomization until disease progression, assessed up to approximately 4 years
DOR
Ramy czasowe: From first documented response until disease progression or death, assessed up to approximately 4 years

Duration of response

From first documented response until disease progression or death, assessed up to approximately 4 years
TTNT
Ramy czasowe: From randomization to start of next anti-CLL/SLL treatment, assessed up to approximately 4 years.

Time to next treatment

From randomization to start of next anti-CLL/SLL treatment, assessed up to approximately 4 years.
EFS
Ramy czasowe: From randomization until an event occurs, assessed up to approximately 4 years.

Event free survival

From randomization until an event occurs, assessed up to approximately 4 years.
Safety and tolerability
Ramy czasowe: From first dose through 30 days after the last dose of study treatment (up to approximately 4 years)

Safety and tolerability will be assessed by the incidence, severity, and relationship of adverse events (AEs) and serious adverse events (SAEs), including deaths; adverse events leading to dose modification or discontinuation; and changes in clinical laboratory parameters. Adverse events will be graded per NCI CTCAE v5.0, with specific monitoring for clinically significant cardiac arrhythmias and bleeding events.

From first dose through 30 days after the last dose of study treatment (up to approximately 4 years)

Inne miary wyników

Miara wyniku
Opis środka
Ramy czasowe
Health related quality of Life
Ramy czasowe: From baseline through end of treatment and follow-up, assessed up to approximately 4 years.

Health-related quality of life (HRQoL) will be assessed using validated patient-reported outcome (PRO) questionnaires to evaluate participants' functioning and symptoms over time. HRQoL endpoints will include change from baseline in overall health status and selected symptom and function domains. For the Global Health Status/QoL and functional scales, higher scores indicate better quality of life and functioning. For symptom scales/items, higher scores indicate greater symptom burden (worse symptoms).

From baseline through end of treatment and follow-up, assessed up to approximately 4 years.

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

23 kwietnia 2026

Zakończenie podstawowe (Szacowany)

30 października 2029

Ukończenie studiów (Szacowany)

30 lipca 2030

Daty rejestracji na studia

Pierwszy przesłany

13 stycznia 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

13 stycznia 2026

Pierwszy wysłany (Rzeczywisty)

15 stycznia 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

12 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

11 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Terminy związane z tym badaniem

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIEZDECYDOWANY

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Tak

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj